KPV: The alpha-MSH Tripeptide With a Strong Preclinical Case and No Human Trials
KPV is an alpha-MSH-derived anti-inflammatory tripeptide with solid animal and cell-based evidence, mostly in gut inflammation, but zero published human trials.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-17The anti-inflammatory tail of alpha-MSH, with an unusually well-described mechanism (PepT1-mediated uptake into inflamed tissue, NF-kB/MAP-kinase inhibition) and consistent preclinical anti-inflammatory data in animal colitis models — but no published human trials, no approval, and a documented chemical instability that makes consumer-product potency uncertain.
Well-described and supported: PepT1-mediated uptake into inflamed tissue (the transporter is up-regulated in inflamed colon), with NF-kB and MAP-kinase inhibition and partly MC1R-independent activity.
Moderate-quality and reasonably consistent across independent animal colitis models plus human-cell mechanistic work, but concentrated in gut inflammation and drug-delivery engineering.
No published human clinical trials; a ClinicalTrials.gov search did not surface registered KPV trials.
Unknown in humans: animal results frequently fail to translate, so benefit in people is unestablished.
Essentially uncharacterised in humans (no controlled human safety data); KPV's chemical instability also means consumer-product potency and degradation products are uncertain.
Roughly two decades of preclinical interest with no registered human trials; reviews explicitly underscore that the evidence remains preclinical.
Strong preclinical support but zero human translation keeps confidence low.
Not approved anywhere; realistic supply is the compounding-pharmacy / research-chemical market. FDA Category 2 nomination later withdrawn — not currently in the active Category 2 table, which is not a clearance and leaves the concerns FDA published standing.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
The anti-inflammatory C-terminal tripeptide of α-MSH, with an unusually well-described mechanism and consistent preclinical anti-inflammatory data (mainly animal colitis models) — but no published human trials and no registered KPV trials.
Safety snapshot
Essentially uncharacterised in humans; effective dose, interactions and long-term effects are unknown, and a documented chemical instability makes consumer-product potency and degradation uncertain.
Regulatory & legality
Not approved anywhere; the realistic supply is the compounding-pharmacy / research-chemical market. The FDA lists KPV among bulk substances nominated to Category 2 whose nominations were withdrawn, so it is not currently in the active Category 2 table; a withdrawal is not approval or clearance and the FDA still publishes the concerns it identified — including that it identified no human exposure data for KPV by any route of administration.
Where claims can exceed the evidence
Anti-inflammatory benefit in people is unestablished; this is not a validated treatment for IBD, autoimmune or inflammatory disease.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
KPV (Lys-Pro-Val) is a tiny three-amino-acid peptide that happens to be the business end of a much larger hormone. It is the C-terminal tail of alpha-melanocyte-stimulating hormone (alpha-MSH), specifically the fragment known as alpha-MSH 11-13. That heritage matters, because most of alpha-MSH's anti-inflammatory punch turns out to live in this short tail [5].
What makes KPV interesting to self-experimenters is the combination of a clean, well-described mechanism and a genuinely consistent body of animal work, set against a glaring gap: there are no published human clinical trials. The research is concentrated in gut inflammation, particularly inflammatory bowel disease (IBD) models, with supporting work in eye and oral-tissue healing. It reads as a promising candidate that, despite roughly two decades of academic interest, has never been put through a proper human test.
This article lays out what the peptide is, what the published science actually shows, what people in the community claim, and where the honest limits sit.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
ARA-290 (Cibinetide): The EPO-Derived Peptide That Targets Nerve Repair Without the Blood Risk
ARA-290 is an EPO-derived peptide with promising but unconfirmed Phase 2 signals in small fibre neuropathy. Mechanistically rational, consistently safe in short trials.
BPC-157: What the Evidence Actually Shows
A clear-eyed look at BPC-157: a peptide with promising rodent healing data, almost no human evidence, and serious regulatory and sourcing caveats.
LL-37: The Body's Own Antibiotic — What the Evidence Actually Shows
LL-37 is the human cathelicidin peptide with rich antimicrobial and wound-healing biology, but solid human data exists only for topical wound use — and it's dual-edged.
TB-500 (Thymosin Beta-4): What the Evidence Actually Shows
TB-500's actin-repair biology is solid in animals, but human evidence exists only for topical eye drops — and injectable use rests on anecdote alone.